{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T01:52:32Z","timestamp":1794707552165,"version":"4.9.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202059"],"award-info":[{"award-number":["82202059"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ibroneuroscience.org","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.neuroscience.2024.09.043","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T23:55:15Z","timestamp":1729122915000},"page":"167-174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Global birth prevalence of Pompe disease: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"563","author":[{"given":"Weijing","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuroscience.2024.09.043_b0005","first-page":"1","article-title":"Prevalence and novel mutations of lysosomal storage disorders in United Arab Emirates: LSD in UAE","volume":"10","author":"Al-Jasmi","year":"2013","journal-title":"JIMD Rep"},{"issue":"1","key":"10.1016\/j.neuroscience.2024.09.043_b0010","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1542\/peds.105.1.e10","article-title":"Incidence of inborn errors of metabolism in British Columbia, 1969\u20131996","volume":"105","author":"Applegarth","year":"2000","journal-title":"Pediatrics"},{"issue":"2\u20133","key":"10.1016\/j.neuroscience.2024.09.043_b0015","first-page":"91","article-title":"Glycogen storage disease type II: birth prevalence agrees with predicted genotype frequency","volume":"2","author":"Ausems","year":"1999","journal-title":"Commun. Genet."},{"issue":"6","key":"10.1016\/j.neuroscience.2024.09.043_b0020","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/sj.ejhg.5200367","article-title":"Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling","volume":"7","author":"Ausems","year":"1999","journal-title":"Eur. J. Human Genet.: EJHG"},{"issue":"2","key":"10.1016\/j.neuroscience.2024.09.043_b0025","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10545-017-0098-3","article-title":"Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy","volume":"41","author":"Burlina","year":"2018","journal-title":"J. Inherited Metabol. Disease"},{"issue":"2","key":"10.1016\/j.neuroscience.2024.09.043_b0030","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/ijns5020024","article-title":"Implementation of second-tier tests in newborn screening for lysosomal disorders in North Eastern Italy","volume":"5","author":"Burlina","year":"2019","journal-title":"Int. J. Neonatal Screen"},{"issue":"1","key":"10.1016\/j.neuroscience.2024.09.043_b0035","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s13023-023-02848-6","article-title":"Genotype, phenotype and treatment outcomes of 17 Malaysian patients with infantile-onset Pompe disease and the identification of 3 novel GAA variants","volume":"18","author":"Chan","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"10.1016\/j.neuroscience.2024.09.043_b0040","doi-asserted-by":"crossref","first-page":"e2410754","DOI":"10.1001\/jamanetworkopen.2024.10754","article-title":"Newborn screening for 6 lysosomal storage disorders in China","volume":"7","author":"Chang","year":"2024","journal-title":"JAMA Network Open"},{"issue":"3","key":"10.1016\/j.neuroscience.2024.09.043_b0045","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ymgme.2012.04.013","article-title":"Algorithm for Pompe disease newborn screening: results from the Taiwan screening program","volume":"106","author":"Chiang","year":"2012","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.neuroscience.2024.09.043_b0050","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1542\/peds.2007-2222","article-title":"Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program","volume":"122","author":"Chien","year":"2008","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.neuroscience.2024.09.043_b0055","doi-asserted-by":"crossref","first-page":"e1116","DOI":"10.1542\/peds.2008-3667","article-title":"Pompe disease in infants: improving the prognosis by newborn screening and early treatment","volume":"124","author":"Chien","year":"2009","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.neuroscience.2024.09.043_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2010.11.053","article-title":"Later-onset pompe disease: early detection and early treatment initiation enabled by newborn screening","volume":"158","author":"Chien","year":"2011","journal-title":"J. Pediatr."},{"issue":"1","key":"10.1016\/j.neuroscience.2024.09.043_b0065","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13023-020-1322-z","article-title":"Newborn screening for Morquio disease and other lysosomal storage diseases: results from the 8-plex assay for 70,000 newborns","volume":"15","author":"Chien","year":"2020","journal-title":"Orphanet J. Rare Diseases"},{"key":"10.1016\/j.neuroscience.2024.09.043_b0070","doi-asserted-by":"crossref","first-page":"1221140","DOI":"10.3389\/fped.2023.1221140","article-title":"An analysis of Pompe newborn screening data: a new prevalence at birth, insight and discussion","volume":"11","author":"Colburn","year":"2024","journal-title":"Front. Pediatr."},{"issue":"1","key":"10.1016\/j.neuroscience.2024.09.043_b0075","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","article-title":"Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis","volume":"15","author":"Crisafulli","year":"2020","journal-title":"Orphanet. J. Rare Dis."},{"issue":"4","key":"10.1016\/j.neuroscience.2024.09.043_b0080","article-title":"Newborn screening for pompe disease: Pennsylvania experience","volume":"6","author":"Ficicioglu","year":"2020","journal-title":"Int. J. Neonatal Screen."},{"key":"10.1016\/j.neuroscience.2024.09.043_b0085","doi-asserted-by":"crossref","unstructured":"Gragnaniello, V., Cazzorla, C., Gueraldi, D., Puma, .A, Loro, C., Porc\u00f9, E., 2023. Light and Shadows in newborn screening for lysosomal storage disorders: eight years of experience in Northeast Italy. 10(1), (2023).","DOI":"10.3390\/ijns10010003"},{"key":"10.1016\/j.neuroscience.2024.09.043_b0090","article-title":"Newborn screening for Pompe disease in Italy: long-term results and future challenges","volume":"33","author":"Gragnaniello","year":"2022","journal-title":"Mol. Genet. Metabol. Rep."},{"key":"10.1016\/j.neuroscience.2024.09.043_b0095","doi-asserted-by":"crossref","unstructured":"Hannah, W.B., Case, L.E., Smith, E.C. et al., 2023. Screening data from 19 patients with late-onset Pompe disease for a phase I clinical trial of AAV8 vector-mediated gene therapy. 64(5), 393-400.","DOI":"10.1002\/jmd2.12391"},{"issue":"7414","key":"10.1016\/j.neuroscience.2024.09.043_b0100","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clin. Research Ed.)"},{"issue":"1","key":"10.1016\/j.neuroscience.2024.09.043_b0105","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jpeds.2014.09.023","article-title":"Lysosomal Storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri","volume":"166","author":"Hopkins","year":"2015","journal-title":"The Journal of Pediatrics"},{"issue":"12","key":"10.1016\/j.neuroscience.2024.09.043_b0110","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/apa.12807","article-title":"Epidemiology of lysosomal storage diseases in Sweden","volume":"103","author":"Hult","year":"1992","journal-title":"Acta paediatrica (Oslo Norway)"},{"issue":"2","key":"10.1016\/j.neuroscience.2024.09.043_b0115","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.neuroscience.2024.09.043_b0120","doi-asserted-by":"crossref","unstructured":"Kohler, L., Puertollano, R., Raben, N., 2018. Pompe Disease: From Basic Science to Therapy. 15(4), 928-942.","DOI":"10.1007\/s13311-018-0655-y"},{"key":"10.1016\/j.neuroscience.2024.09.043_b0125","doi-asserted-by":"crossref","unstructured":"Labella, B., Cotti Piccinelli, S., Risi, B., Caria, F., Damioli, S., 2023. A comprehensive update on late-onset pompe disease. 13(9), (2023).","DOI":"10.3390\/biom13091279"},{"key":"10.1016\/j.neuroscience.2024.09.043_b0130","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13023-014-0173-x","article-title":"A systematic review of the prevalence of Morquio A syndrome: challenges for study reporting in rare diseases","volume":"9","author":"Leadley","year":"2014","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.neuroscience.2024.09.043_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2021.12.072","article-title":"Outcome of later-onset pompe disease identified through newborn screening","author":"Lee","year":"2022","journal-title":"J. Pediatr."},{"issue":"1","key":"10.1016\/j.neuroscience.2024.09.043_b0140","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00415-017-8686-6","article-title":"Pompe disease in Austria: clinical, genetic and epidemiological aspects","volume":"265","author":"L\u00f6scher","year":"2018","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.neuroscience.2024.09.043_b0145","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/(SICI)1096-8628(19980827)79:1<69::AID-AJMG16>3.0.CO;2-K","article-title":"Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease","volume":"79","author":"Martiniuk","year":"1998","journal-title":"Am. J. Med. Genet."},{"issue":"9813","key":"10.1016\/j.neuroscience.2024.09.043_b0150","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0140-6736(11)61266-X","article-title":"Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria","volume":"379","author":"Mechtler","year":"2012","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.neuroscience.2024.09.043_b0155","doi-asserted-by":"crossref","unstructured":"Meikle, P., Hopwood, J., Clague, A,, Carey W., 1999. Prevalence of lysosomal storage disorders. Jama 281(3), 249-254.","DOI":"10.1001\/jama.281.3.249"},{"issue":"8","key":"10.1016\/j.neuroscience.2024.09.043_b0160","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s10038-019-0603-7","article-title":"Newborn screening for Pompe disease in Japan: report and literature review of mutations in the GAA gene in Japanese and Asian patients","volume":"64","author":"Momosaki","year":"2019","journal-title":"J. Human Genet."},{"key":"10.1016\/j.neuroscience.2024.09.043_b0165","doi-asserted-by":"crossref","DOI":"10.1002\/cpdd.1314","article-title":"Pharmacokinetics of alglucosidase alfa manufactured at the 4000-L scale in participants with pompe disease: a phase 3\/4 open-label study","author":"Nicolas","year":"2023","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"3","key":"10.1016\/j.neuroscience.2024.09.043_b0170","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet. Med.: Off. J. Am. College Med. Genet."},{"key":"10.1016\/j.neuroscience.2024.09.043_b0175","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372 n71","author":"Page","year":"2021","journal-title":"BMJ (Clin. Res. Ed.)"},{"key":"10.1016\/j.neuroscience.2024.09.043_b0180","article-title":"Carrier frequency and predicted genetic prevalence of Pompe disease based on a general population database","volume":"27","author":"Park","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.neuroscience.2024.09.043_b0185","doi-asserted-by":"crossref","unstructured":"Pillai, N.R., Fabie, N.a.V., Kaye, T.V., et al., 2023. Disparities in late and lost: Pediatricians' role in following Pompe disease identified by newborn screening. Mol. Genet. Metabol. doi: 10.1016\/j.ymgme.2023.107633 107633 (2023).","DOI":"10.1016\/j.ymgme.2023.107633"},{"issue":"2","key":"10.1016\/j.neuroscience.2024.09.043_b0190","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.ejhg.5201044","article-title":"Prevalence of lysosomal storage diseases in Portugal","volume":"12","author":"Pinto","year":"2004","journal-title":"Eur. J. Human Genet.: EJHG"},{"issue":"1\u20132","key":"10.1016\/j.neuroscience.2024.09.043_b0195","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s004399900075","article-title":"The frequency of lysosomal storage diseases in The Netherlands","volume":"105","author":"Poorthuis","year":"1999","journal-title":"Human Genetics"},{"issue":"12","key":"10.1016\/j.neuroscience.2024.09.043_b0200","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1474-4422(21)00358-6","article-title":"New therapies for Pompe disease: are we closer to a cure?","volume":"20","author":"Puertollano","year":"2021","journal-title":"The Lancet. Neurology"},{"issue":"4","key":"10.1016\/j.neuroscience.2024.09.043_b0205","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3233\/JND-180336","article-title":"Low prevalence estimates of late-onset glycogen storage disease type II in French-speaking Belgium are not due to missed diagnoses","volume":"5","author":"Remiche","year":"2018","journal-title":"J. Neuromusc. Diseases"},{"issue":"2","key":"10.1016\/j.neuroscience.2024.09.043_b0210","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF00445157","article-title":"Incidence of glycogen storage disease in the German Federal Republic","volume":"120","author":"Schaub","year":"1975","journal-title":"Zeitschrift Fur Kinderheilkunde"},{"issue":"6","key":"10.1016\/j.neuroscience.2024.09.043_b0215","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s10545-018-0243-7","article-title":"Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study","volume":"41","author":"Semplicini","year":"2018","journal-title":"J Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.neuroscience.2024.09.043_b0220","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/ijns6010009","article-title":"The first year experience of Newborn screening for pompe disease in California","volume":"6","author":"Tang","year":"2020","journal-title":"Int. J. Neonatal Screening"},{"issue":"4","key":"10.1016\/j.neuroscience.2024.09.043_b0225","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/MPH.0000000000002506","article-title":"Global epidemiology of gaucher disease: an updated systematic review and meta-analysis","volume":"45","author":"Wang","year":"2023","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.neuroscience.2024.09.043_b0230","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/8904_2012_130","article-title":"Newborn screening for lysosomal storage disorders in Hungary","volume":"6","author":"Wittmann","year":"2012","journal-title":"JIMD Reports"},{"issue":"1","key":"10.1016\/j.neuroscience.2024.09.043_b0235","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ajmg.a.36197","article-title":"A large-scale nationwide newborn screening program for pompe disease in Taiwan: towards effective diagnosis and treatment","volume":"164","author":"Yang","year":"2014","journal-title":"Am. J. Med. Genet., Part A"}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452224004962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452224004962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T05:32:39Z","timestamp":1734586359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306452224004962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":47,"alternative-id":["S0306452224004962"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2024.09.043","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Global birth prevalence of Pompe disease: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuroscience.2024.09.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of International Brain Research Organization (IBRO).","name":"copyright","label":"Copyright"}]}}